After the match ended, followed by much drama, he sat down for the press conference and responded to questions, a few of them ...

Multinational pharmaceutical firms are pulling pack or pausing investments in the UK, blaming a lack of competitive drug ...

South SF lab uses AI to strip hallucinations from psychedelics while keeping therapeutic benefits. Silicon Valley ...

FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the ...

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout ...

A letter to the Competition and Markets Authority from three NGOs accuses companies of “suspected” anticompetitive behavior.

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fisca ...

Durban, 52 years old, was part of a new generation of leaders at Silver Lake who took the helm in 2011. He and Greg Mondre ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...